Last reviewed 2026-04-22 · How we verify

Nitrendipine/Atenolol

This combination drug reduces blood pressure by blocking calcium channels (nitrendipine) to relax blood vessels and blocking beta-adrenergic receptors (atenolol) to reduce heart rate and cardiac output.

This combination drug reduces blood pressure by blocking calcium channels (nitrendipine) to relax blood vessels and blocking beta-adrenergic receptors (atenolol) to reduce heart rate and cardiac output. Used for Hypertension.

At a glance

Mechanism of action

Nitrendipine is a dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance. Atenolol is a selective beta-1 adrenergic antagonist that decreases heart rate, contractility, and blood pressure. The combination provides complementary antihypertensive effects through different mechanisms.

Approved indications

• Hypertension

Common side effects

• Headache
• Dizziness
• Fatigue
• Peripheral edema
• Bradycardia
• Flushing

Key clinical trials

• The Effect of Nitrendipine/Atenolol Combination on Blood Pressure Variability. (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Nitrendipine/Atenolol CI brief — competitive landscape report
• Nitrendipine/Atenolol updates RSS · CI watch RSS
• Shanghai Jiao Tong University School of Medicine portfolio CI